Regeneron Pharmaceuticals, Inc. Share Price

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
883.2 USD -0.84% Intraday chart for Regeneron Pharmaceuticals, Inc. -1.52% +0.56%
Sales 2024 * 13.91B 1,160B Sales 2025 * 14.86B 1,239B Capitalization 95.28B 7,945B
Net income 2024 * 4.32B 360B Net income 2025 * 4.53B 378B EV / Sales 2024 * 6.23 x
Net cash position 2024 * 8.68B 724B Net cash position 2025 * 13.36B 1,114B EV / Sales 2025 * 5.51 x
P/E ratio 2024 *
23.9 x
P/E ratio 2025 *
22.6 x
Employees 13,450
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.84%
1 week-1.52%
Current month-8.24%
1 month-8.34%
3 months-6.05%
6 months+11.51%
Current year+0.56%
More quotes
1 week
875.23
Extreme 875.225
915.70
1 month
875.23
Extreme 875.225
970.79
Current year
871.39
Extreme 871.39
998.33
1 year
684.81
Extreme 684.805
998.33
3 years
478.40
Extreme 478.4
998.33
5 years
271.37
Extreme 271.37
998.33
10 years
269.50
Extreme 269.5
998.33
More quotes
Managers TitleAgeSince
Founder 64 08/88/08
Chief Executive Officer 71 08/88/08
Director of Finance/CFO 54 01/03/01
Members of the board TitleAgeSince
Director/Board Member 71 12/10/12
Chief Executive Officer 71 08/88/08
Director/Board Member 82 01/91/01
More insiders
Date Price Change Volume
26/24/26 883.2 -0.84% 505,652
25/24/25 890.7 -1.75% 576,565
24/24/24 906.5 -0.09% 373,718
23/24/23 907.3 +0.80% 341,220
22/24/22 900.2 +0.37% 351,366

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
883.2 USD
Average target price
1,038 USD
Spread / Average Target
+17.54%
Consensus